Search results

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency Editor’s summary Interrogating Infection in Immunosuppression. Individuals who are immunosuppressed remain at increased risk of severe COVID-19, but this heterogenous patient pool should not be considered a...

Unfortunately, the data is pointing towards exactly the opposite direction. It seems to reduce nothing in regards to ME/CFS and only things related to a severe acute infection. In this recent presentation by the lead author of the Metformin studies the researcher is very open about the fact...

Haven't read the study but low HGS was one of the markers leading to a worse prognosis in Scheibenbogen's long-term ME/CFS-like LC study: Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort, 2023.

Homepage:https://www.inselfilm.de/portfolio-item/chronically-ignored/ »Chronically Ignored« is an investigative documentary about a dark chapter in the history of medicine. Why has a devastating, multi-systemic disease like ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) been...

The idea here will be that things such as chronic stress lead to more negative health outcomes. It's very reasonable that, that will be true to some degree especially if there are higher suidice rates, as is the case here. Of course there will be significant confounders as well, such as...

A new artice in Nature discussing the hope of curing autoimmune diseases, includes a discussion on CAR-T therapy and CAAR-T therapy and why one should be careful about being too optimistic: Can autoimmune diseases be cured? Scientists see hope at last.

At 11:25 on this Twitter interview Ely states that he has received 30 million from the NIH to run the Baricitinib trial, so that should confirm it.

Scheibenbogen is also going to conduct a Baricitinib trial (at least those were her original plans https://pbs.twimg.com/media/FbtnFb8WIAEQq4G?format=jpg&name=large). Do you have details on this? The grant amount seems to be for the whole time period (at least that's what the webpage seems to...

REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC) The largest study on Long-Covid initiated by Wes Ely is starting in the upcoming months. In this large (n=550) Randomized, placebo-controlled, double-blind, parallel-design superiority design Phase 3 trial for Long-Covid 4 mg of...

Abstract Context In some patients, symptoms may persist after COVID-19, defined as long COVID. Its pathogenesis is still debated and many hypotheses have been raised. Objective Our primary objective was to evaluate the corticotroph and somatotroph functions of patients previously infected with...

Can't read this, but I'd like to know how they measured antiadrenergic autoantibodies since for Celltrend at least it's known there's no difference in the levels of POTS patients and healthy controls. Isn't it also kind of obvious whether you're getting the placebo or the real thing since one...

If I remember the above study correctly the authors claim that most mathematical models are systems of ODEs and you state that some inherent properties of autoimmune diseases are stochastic and should be modelled as such. Unless I’m missing something that would mean there’s some sort of gap in...

No information on whether this is ill-intentioned or not as far as I can tell.

I agree, which is why I argued that thus far I wouldn't call anything "change" yet. Apart from politics the medical research community, doctors and healthcare sectors are also quite important, there seems to be very little progress there and the progress that exists, may just be temporary and...

Could the so-called "Covid-toes" be a sign of that or would it be more likely that, that would hav something to do with blood pooling or something else?

@Jonathan Edwards do you think it would be fruitful to pick an autoimmune disease that is somewhat better understood and try to model things from there? Is there sufficient understanding at some scale or on a subset of something to have a meaningful model? I don't think the goal could be for...

Now published in Nature Scientific Reports as Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19. There's substantial changes when compared to the 3 year older preprint.

Now published as 3D Holo-tomographic Mapping of COVID-19 Microclots in Blood to Assess Disease Severity.

I agree that those things could all be considered wins and these things happening is certainly better than them not happening, but those wins don't mean anything is changing, they might just be temporary effects that are irrelevant in the grand scheme of things. It's possible that things will...

Cohort Follow-up of 113 hospitalised Covid-19 patients for 1 year (measurements taken at 0, 6 and 12 months). Thus according to most studies one would expect roughly 5-15 of these to develop LC with maybe 0-2 having severely disabling LC. However, one third of this cohort also had a severe...